

# PHARMACY POLICY STATEMENT

## Marketplace

<b>DRUG NAME</b>	<b>Rebyota (fecal microbiota, live - jslm)</b>
BENEFIT TYPE STATUS	Medical

DATE	ACTION/DESCRIPTION
01/30/2023	New policy for Rebyota created.
07/13/2023	Added trial of Zinplava.

References:

1. Rebyota. Package Insert. Ferring Pharmaceuticals Inc.; 2022. Accessed January 30, 2023.
2. Rebyota. Prescribing information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
3. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America